Abstract
Idiopathic pulmonary fibrosis (IPF) is a complex disease that is limited to the lungs. The natural history of IPF is one of slow and progressive decline in lung function with most patients dying from respiratory failure within 2–5years of diagnosis. Several clinical factors can be helpful in predicting prognosis. Changes in symptoms, pulmonary physiology, and chest imaging can be used as markers and are helpful in predicting survival. With the advent of two antifibrotic medications, the disease course of IPF may be altered, with a slower decline in lung function, a delay in time to acute exacerbations, and an increase in survival time.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
